High-risk human papillomavirus E6/E7 mRNA and L1 DNA as markers of residual/recurrent cervical intraepithelial neoplasia

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 346-352

  Persson, Maria ^a   Wendel, Sophia Brismar ^a   Ljungblad, Linda ^a   Johansson, Bo ^a   Weiderpass, Elisabete ^b,c,d,e   Andersson, Sonia ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c CANCER REGISTRY OF NORWAY   (Norway)

^d UNIVERSITY OF TROMSØ   (Norway)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

CIN; Conization; E6 E7 mRNA; Genotyping; Human papillomavirus; Recurrence; Residual

Indexed keywords

CAPSID PROTEIN L1; MESSENGER RNA; PROTEIN E6; PROTEIN E7;

ACCURACY; ADULT; ARTICLE; CANCER GRADING; CANCER RECURRENCE; DISEASE MARKER; ELECTROSURGERY; GENE EXPRESSION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 66; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADULT; ALPHAPAPILLOMAVIRUS; CAPSID PROTEINS; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; CONIZATION; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 84861561876     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1755     Document Type: Article

References (37)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M and Bray F and Ferlay J: Worldwide burden of cervical cancer in 2008. Ann Oncol 22: 2675-2686, 2011.
2. Hemminki K, Li X and Vaittinen P: Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958-1996. Eur J Obstet Gynecol Reprod Biol 101: 64-69, 2002. (Pubitemid 34142249)
3. Miller MG, Sung HY, Sawaya GF, Kearney KA, Kinney W and Hiatt RA: Screening interval and risk of invasive squamous cell cervical cancer. Obstet Gynecol 101: 29-37, 2003. (Pubitemid 36057085)
4. Walboomers JM, Jacobs MV, Manos MM, et al: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19, 1999. (Pubitemid 29406813)
5. zur Hausen H: Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
6. Vousden K: Interactions of human papillomavirus transforming proteins with the products of tumor suppressor genes. FASEB J 7: 872-879, 1993.
7. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T and Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70: 923-935, 1992.
8. Peitsaro P, Johansson B and Syrjanen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40: 886-891, 2002. (Pubitemid 34208640)
9. Dowhanick JJ, McBride AA and Howley PM: Suppression of cellular proliferation by the papillomavirus E2 protein. J Virol 69: 7791-7799, 1995.
10. Nakagawa S, Yoshikawa H, Yasugi T, et al: Ubiquitous presence of E6 and E7 transcripts in human papillomavirus-positive cervical carcinomas regardless of its type. J Med Virol 62: 251-258, 2000.
11. Cuschieri KS, Whitley MJ and Cubie HA: Human papilloma-virus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J Med Virol 73: 65-70, 2004. (Pubitemid 38429149)
12. Sotlar K, Selinka HC, Menton M, Kandolf R and Bultmann B: Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol Oncol 69: 114-121, 1998. (Pubitemid 28246996)
13. Andersson S, Dillner L, Elfgren K, Mints M, Persson M and Rylander E: A comparison of the human papillomavirus test and Papanicolaou smear as a second screening method for women with minor cytological abnormalities. Acta Obstet Gynecol Scand 84: 996-1000, 2005. (Pubitemid 41400303)
14. Sotlar K, Diemer D, Stubner A, et al: Detection of high-risk human papillomavirus (HPV) E6 and E7 oncogene transcripts increases the specificity of the detection of a cervical intraepithelial neoplasia (CIN). Verh Dtsch Ges Pathol 89: 195-200, 2005 (In German).
15. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G and Dillner J: Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24 (Suppl 3): S3/78-89, 2006.
16. Zielinski GD, Bais AG, Helmerhorst TJ, et al: HPV testing and monitoring of women after treatment of CIN 3: review of the literature and meta-analysis. Obstet Gynecol Surv 59: 543-553, 2004. (Pubitemid 38802827)
17. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W and Dillner J: Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 99 (3 Suppl 1): S7-S11, 2005. (Pubitemid 41774340)
18. Brismar S, Johansson B, Borjesson M, Arbyn M and Andersson S: Follow-up after treatment of cervical intraepithelial neoplasia by human papillomavirus genotyping. Am J Obstet Gynecol 201: 17 e1-8, 2009.
19. Mints M, Gaberi V and Andersson S: Miniconization procedure with C-LETZ conization electrode for treatment of cervical intraepithelial neoplasia: a Swedish study. Acta Obstet Gynecol Scand 85: 218-223, 2006. (Pubitemid 43879246)
20. Arbyn M, Herbert A, Schenck U, et al: European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 18: 133-139, 2007. (Pubitemid 46934510)
21. Richart RM: Cervical intraepithelial neoplasia. Pathol Annu 8: 301-328, 1973.
22. Solomon D, Davey D, Kurman R, et al: The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119, 2002. (Pubitemid 34437346)
23. Söderlund-Strand A, Rymark P, Andersson P, Dillner J and Dillner L: Comparison between the Hybrid Capture II test and a PCR-based human papillomavirus detection method for diagnosis and posttreatment follow-up of cervical intraepithelial neoplasia. J Clin Microbiol 43: 3260-3266, 2005. (Pubitemid 40981333)
24. Monsonego J, Pollini G, Evrard MJ, Sednaoui P, Monfort L, Zerat L and Syrjänen K: Detection of human papillomavirus genotypes among high-risk women: a comparison of hybrid capture and linear array tests. Sex Transm Dis 35: 521-527, 2008. (Pubitemid 351670554)
25. Muñoz N, Bosch FX, de Sanjosé S, et al: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003. (Pubitemid 36159887)
26. Getman D, Aiyer A, Dockter J, Giachetti C, Zhang F and Ginocchio CC: Efficiency of the APTIMA HPV assay for detection of HPV RNA and DNA targets. J Clin Virol 45 (Suppl 1): S49-S54, 2009.
27. Dockter J, Schroder A, Eaton B, Wang A, Sikhamsay N, Morales L and Giachetti C: Analytical characterization of the APTIMA HPV Assay. J Clin Virol 45 (Suppl 1): S39-S47, 2009.
28. Castle PE, Dockter J, Giachetti C, et al: A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin Cancer Res 13: 2599-2605, 2007. (Pubitemid 46788025)
29. Bosch FX and Muñoz N: The viral etiology of cervical cancer. Virus Res 89: 183-190, 2002. (Pubitemid 35351537)
30. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF and Hagmar B: Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol Biomarkers Prev 14: 367-372, 2005. (Pubitemid 40270098)
31. Ratnam S, Coutlee F, Fontaine D, et al: Aptima HPV E6/E7 mRNA test is as sensitive as Hybrid Capture 2 Assay but more specific at detecting cervical precancer and cancer. J Clin Microbiol 49: 557-564, 2011.
32. Andersson E, Karrberg C, Radberg T, et al: Type-specific human papillomavirus E6/E7 mRNA detection by real-time PCR improves identification of cervical neoplasia. J Clin Microbiol 49: 3794-3799, 2011.
33. Andersson S, Hansson B, Norman I, et al: Expression of E6/E7 mRNA from 'high risk' human papillomavirus in relation to CIN grade, viral load and p16INK4a. Int J Oncol 29: 705-711, 2006.
34. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, et al: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20-25, 1999. (Pubitemid 29304297)
35. Dockter J, Schroder A, Hill C, Guzenski L, Monsonego J and Giachetti C: Clinical performance of the APTIMA HPV Assay for the detection of high-risk HPV and high-grade cervical lesions. J Clin Virol 45 (Suppl 1): S55-S61, 2009.
36. Verguts J, Bronselaer B, Donders G, Arbyn M, Van Eldere J, Drijkoningen M and Poppe W: Prediction of recurrence after treatment for high-grade cervical intraepithelial neoplasia: the role of human papillomavirus testing and age at conisation. BJOG 113: 1303-1307, 2006. (Pubitemid 44581521)
37. Tropé A, Jonassen CM, Sjoborg KD, Nygard M, Dahl FA, Alfsen GC and Lie AK: Role of high-risk human papillomavirus (HPV) mRNA testing in the prediction of residual disease after conisation for high-grade cervical intraepithelial neoplasia. Gynecol Oncol 123: 257-262, 2011.